" The current COVID19 pandemic has imposed in a few months a global burden on humanity. A vaccine is urgently needed to protect people, communities, healthcare systems, and economies. In this context, Univercells joined forces with Reithera and Leukocare to develop and manufacture a novel adenovirus-based vaccine against COVID19. This vaccine candidate is expected to enter in clinical trials during summer 2020 and production to start soon after. Capitalizing on the bioproduction technologies of its newly created subsidiary Univercells Technologies, Univercells will produce at large-scale the vaccine candidate in Jumet. This site with 15,000 m² GMP capabilities offers the capacity to be ready for rapid response programs. Approximately 6 million doses are expected to be available in early 2021. The intention with these doses will be to vaccinate the most exposed people such as medical and healthcare professionals and highly vulnerable individuals. "
Read more: Hugues Bultot, CEO